Adult | Age
Item
adult patients >/= 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Renal Cell Carcinoma Advanced unresectable | Metastatic Renal Cell Cancer unresectable | Clear cell Component Histology | Sarcomatoid Component Histology | Systemic therapy Absent | Adjuvant therapy Absent
Item
unresectable advanced or metastatic renal cell carcinoma with component of clear cell histology and/or component of sarcomatoid histology that has not been previously treated with any systemic agents, including treatment in the adjuvant setting
boolean
C0007134 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1519810 (UMLS CUI [1,3])
C0278678 (UMLS CUI [2,1])
C1519810 (UMLS CUI [2,2])
C0229473 (UMLS CUI [3,1])
C1705248 (UMLS CUI [3,2])
C0344441 (UMLS CUI [3,3])
C1519183 (UMLS CUI [4,1])
C1705248 (UMLS CUI [4,2])
C0344441 (UMLS CUI [4,3])
C1515119 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C0677850 (UMLS CUI [6,1])
C0332197 (UMLS CUI [6,2])
Measurable Disease
Item
measurable disease, as defined by recist v1.1
boolean
C1513041 (UMLS CUI [1])
Karnofsky Performance Status
Item
karnofsky performance score >/= 70
boolean
C0206065 (UMLS CUI [1])
Hematologic function | Organ function
Item
adequate hematologic and end-organ function as defined by protocol
boolean
C0221130 (UMLS CUI [1])
C0678852 (UMLS CUI [2])
Childbearing Potential Contraceptive methods | Gender Contraceptive methods | MPDL3280A | Avastin | bevacizumab | sunitinib
Item
women of childbearing potential and male patients must agree to use adequate methods of contraception as defined by protocol during the treatment period and for at least 6 months after the last dose of mpdl3280a or avastin (bevacizumab) for patients randomized to arm a, or at least 90 days after the last dose of mpdl3280a monotherapy for patients randomized to arm b, or at least 30 days after the last dose of sunitinib for patients randomized to arm c.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C3827082 (UMLS CUI [3])
C1135130 (UMLS CUI [4])
C0796392 (UMLS CUI [5])
C1176020 (UMLS CUI [6])
Therapeutic radiology procedure Renal Cell Carcinoma | Exception Therapeutic radiology procedure Fraction Single | Exception Indication Pain control
Item
radiotherapy for rcc within 28 days prior to cycle 1, day 1 with the exception of: single-fraction radiotherapy given for the indication of pain control
boolean
C1522449 (UMLS CUI [1,1])
C0007134 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C1710555 (UMLS CUI [2,3])
C0205171 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C3146298 (UMLS CUI [3,2])
C1304888 (UMLS CUI [3,3])
Brain Neoplasms CT | Metastatic malignant neoplasm to brain CT | Spinal Cord Neoplasms CT | Secondary malignant neoplasm of spinal cord CT | Leptomeningeal Neoplasms CT | Brain Neoplasms MRI | Metastatic malignant neoplasm to brain MRI | Spinal Cord Neoplasms MRI | Secondary malignant neoplasm of spinal cord MRI | Leptomeningeal Neoplasms MRI | Brain Neoplasms Diagnostic radiologic examination | Metastatic malignant neoplasm to brain Diagnostic radiologic examination | Spinal Cord Neoplasms Diagnostic radiologic examination | Secondary malignant neoplasm of spinal cord Diagnostic radiologic examination | Leptomeningeal Neoplasms Diagnostic radiologic examination
Item
known active malignancies or metastasis of the brain or spinal cord or leptomeningeal disease, as determined by ct or mri evaluation during screening and prior radiographic assessments
boolean
C0006118 (UMLS CUI [1,1])
C0040405 (UMLS CUI [1,2])
C0220650 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
C0037930 (UMLS CUI [3,1])
C0040405 (UMLS CUI [3,2])
C0347016 (UMLS CUI [4,1])
C0040405 (UMLS CUI [4,2])
C0751297 (UMLS CUI [5,1])
C0040405 (UMLS CUI [5,2])
C0006118 (UMLS CUI [6,1])
C0024485 (UMLS CUI [6,2])
C0220650 (UMLS CUI [7,1])
C0024485 (UMLS CUI [7,2])
C0037930 (UMLS CUI [8,1])
C0024485 (UMLS CUI [8,2])
C0347016 (UMLS CUI [9,1])
C0024485 (UMLS CUI [9,2])
C0751297 (UMLS CUI [10,1])
C0024485 (UMLS CUI [10,2])
C0006118 (UMLS CUI [11,1])
C0043299 (UMLS CUI [11,2])
C0220650 (UMLS CUI [12,1])
C0043299 (UMLS CUI [12,2])
C0037930 (UMLS CUI [13,1])
C0043299 (UMLS CUI [13,2])
C0347016 (UMLS CUI [14,1])
C0043299 (UMLS CUI [14,2])
C0751297 (UMLS CUI [15,1])
C0043299 (UMLS CUI [15,2])
Pleural effusion Uncontrolled | Pericardial effusion | Ascites Requirement Drainage Repeated
Item
uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
boolean
C0032227 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0031039 (UMLS CUI [2])
C0003962 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
C0013103 (UMLS CUI [3,3])
C0205341 (UMLS CUI [3,4])
Hypercalcemia Uncontrolled | Hypercalcemia Symptomatic
Item
uncontrolled hypercalcemia or symptomatic hypercalcemia
boolean
C0020437 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0020437 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Malignant Neoplasms | Exception Renal Cell Carcinoma | Exception Low Risk Metastasis | Exception Low Risk Death | Exception Outcome Curative Expected
Item
malignancies other than rcc within 5 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death, treated with expected curative outcome
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007134 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C3538919 (UMLS CUI [3,2])
C0027627 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C3538919 (UMLS CUI [4,2])
C0011065 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C1274040 (UMLS CUI [5,2])
C1880198 (UMLS CUI [5,3])
C1517001 (UMLS CUI [5,4])
Life Expectancy
Item
life expectancy of < 12 weeks
boolean
C0023671 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant and lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Allergic Reaction Severe Chimeric antibody | Anaphylaxis Severe Chimeric antibody | Severe allergy Chimeric antibody | Allergic Reaction Severe Humanized Antibodies | Anaphylaxis Severe Humanized Antibodies | Severe allergy Humanized Antibodies | Allergic Reaction Severe Fusion protein | Anaphylaxis Severe Fusion protein | Severe allergy Fusion protein
Item
history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
boolean
C1527304 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0598622 (UMLS CUI [1,3])
C0002792 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0598622 (UMLS CUI [2,3])
C2945656 (UMLS CUI [3,1])
C0598622 (UMLS CUI [3,2])
C1527304 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C2985546 (UMLS CUI [4,3])
C0002792 (UMLS CUI [5,1])
C0205082 (UMLS CUI [5,2])
C2985546 (UMLS CUI [5,3])
C2945656 (UMLS CUI [6,1])
C2985546 (UMLS CUI [6,2])
C1527304 (UMLS CUI [7,1])
C0205082 (UMLS CUI [7,2])
C0162768 (UMLS CUI [7,3])
C0002792 (UMLS CUI [8,1])
C0205082 (UMLS CUI [8,2])
C0162768 (UMLS CUI [8,3])
C2945656 (UMLS CUI [9,1])
C0162768 (UMLS CUI [9,2])
Autoimmune Disease | Exception Hypothyroidism Relationship Autoimmune Diseases | Exception Thyroid hormone replacement therapy Dose Stable
Item
history of autoimmune disease (patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study)
boolean
C0004364 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0020676 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0004364 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C2242640 (UMLS CUI [3,2])
C0178602 (UMLS CUI [3,3])
C0205360 (UMLS CUI [3,4])
Bevacizumab Specific Exclusion Criteria | Sunitinib Specific Exclusion Criteria
Item
bevacizumab- and sunitinib-specific exclusions:
boolean
C0796392 (UMLS CUI [1,1])
C0205369 (UMLS CUI [1,2])
C0680251 (UMLS CUI [1,3])
C1176020 (UMLS CUI [2,1])
C0205369 (UMLS CUI [2,2])
C0680251 (UMLS CUI [2,3])
Poor hypertension control
Item
inadequately controlled hypertension
boolean
C0421190 (UMLS CUI [1])
Hypertensive crisis | Hypertensive Encephalopathy
Item
prior history of hypertensive crisis or hypertensive encephalopathy
boolean
C0020546 (UMLS CUI [1])
C0151620 (UMLS CUI [2])